NMT posts encouraging early data on PFO implant BioSTAR
This article was originally published in Clinica
Executive Summary
NMT Medical says that positive findings are now available to support the use of its bioabsorbable cardiac defect repair technology, BioSTAR. The minimally-invasive, catheter-based implant is currently being investigated in a multi-centred clinical trial, called BEST (BioSTAR Evaluation Study), as a means of closing a patent foramen ovale (PFO).